Source link : https://newshealth.biz/health-news/tazemetostat-pulled-from-market-over-secondary-cancer-risk/
Options remain for patients with relapsed/refractory follicular lymphoma, but tazemetostat was the only drug approved specifically for epithelioid sarcoma. Medscape Medical News Source link : https://www.medscape.com/viewarticle/tazemetostat-pulled-market-over-secondary-cancer-risk-2026a10007bu?src=rss Author : Publish date : 2026-03-10 14:16:00 Copyright for syndicated content belongs to the linked Source.
The post Tazemetostat Pulled From Market Over Secondary Cancer Risk first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-10 14:16:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8